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Abstract
Background: Cells of the tumor microenvironment are recognized as important determinants of the tumor biology.
The adjacent non-malignant cells can regulate drug responses of the cancer cells by secreted paracrine factors and
direct interactions with tumor cells.
Results: Human mesenchymal stromal cells (MSC) actively contribute to tumor microenvironment. Here we focused
on their response to chemotherapy as during the treatment these cells become affected. We have shown that the
secretory phenotype and behavior of mesenchymal stromal cells influenced by cisplatin differs from the naïve MSC.
MSC were more resistant to the concentrations of cisplatin, which was cytotoxic for tumor cells. They did not undergo
apoptosis, but a part of MSC population underwent senescence. However, MSC pretreatment with cisplatin led to
changes in phosphorylation profiles of many kinases and also increased secretion of IL-6 and IL-8 cytokines.
These changes in cytokine and phosphorylation profile of MSC led to increased chemoresistance and stemness of
breast cancer cells.
Conclusion: Taken together here we suggest that the exposure of the chemoresistant cells in the tumor
microenvironment leads to substantial alterations and might lead to promotion of acquired microenvironment-
mediated chemoresistance and stemness.
Keywords: Adipose tissue-derived mesenchymal stromal cells, Apoptosis, Cell signaling, Human breast cancer,
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Background
Breast cancer still remains a clinical challenge with consid-
erable mortality as well as a treatment-associated morbidity.
Along with a surgery and radiotherapy, the chemotherapy
remains a crucial clinical modality. Better understanding of
mechanisms involved in the regulation of the drug sensitiv-
ity is important for improved efficiency of cancer treatment.
Recent data indicated that tumor microenvironment pro-
vides both biochemical and mechanical signaling cues to
the cells and it impacts substantially on the outcome of the
therapy. Direct cellular interactions and secreted paracrine
factors can stimulate the tumor growth and contribute to
the environment-mediated drug resistance [1–4]. There are
only few studies which investigated the role of the tumor
microenvironment in determining the therapeutic outcome,
and, therefore, we need more experiments to predict the
drug responses in patients. Pro-survival features of the stro-
mal microenvironment may prevent efficient induction of
the cell death in the tumor cells and compromise apoptotic
pathways in the tumor cells embedded within the micro-
environment [5, 6].
Tumor microenvironment is composed of many differ-
ent types of non-malignant cells including mesenchymal
stromal cells (MSC) [7]. MSC preferentially reside in
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perivascular niches of nearly all kinds of human tissues
and display homing and engraftment potential to the in-
jury sites in a number of pathological conditions [8].
MSC are considered cellular all-round supporters by
which these cells exhibit significant sensitivity to extracel-
lular and intracellular signals [9]. Studies by Castells et al.
[5], Roodhart et al. [10] and our own data [11] indicated
that MSC alter the chemosensitivity in vitro and in vivo. It
was shown that carcinoma-associated mesenchymal stro-
mal cells are able to protect ovarian cancer cells from
carboplatin-induced apoptosis via inhibition of effector
caspases activation and apoptosis blocade [5]. Roodhart et
al. [10] have shown the production of unique fatty acids
by endogenous platinum-activated mesenchymal stromal
cells, that confer resistance to multiple types of chemo-
therapy. Moreover, Gilbert et al. [12] suggested that the
chemotherapeutic drug doxorubicin leads to an acute
stress response in the cells of the tumor microenviron-
ment which results in the induction of chemoresistance in
multiple myeloma. Similar processes, such as a stress re-
sponse in the cells from the stromal tumor compartment
including the MSC, might be involved in solid tumors as
well. The MSC were shown to secrete high levels of protu-
morigenic cytokines IL-6 and IL-8 that might contribute
to the chemoresistance and stemness, specifically if upreg-
ulated upon drug exposure [13–16]. Cancer stem cells
(CSCs) can be identified and characterized using different
methodologies focusing on chemoresistance, multipo-
tency, tumorigenicity, stem cell gene expression and alde-
hyde dehydrogenase (ALDH) activity [17, 18].
The secretome of chemo- naïve cells and stromal
compartment differs significantly from the secretion of
chemotherapy-exposed cells. Although it was shown
that therapy-induced secretome of tumor cells can pro-
mote resistance and tumor progression [19], recent evi-
dence indicates that tumor-stroma coalition also play
an important role in developing of drug resistance [1].
Moreover, it was reported that the MSC represented che-
moresistant cells that could withstand cytotoxic stress,
possessed considerable plasticity and supported tissue re-
generation [20, 21]. Nevertheless, the acute secretory stress
response in drug-exposed MSC and the potential effect on
neighboring cells have not been examined in detail so far.
Similarly to the situation in lymphatic tissues, chemother-
apy might activate multiple pathways which lead to the
alteration in MSC secretome and formation of resistant
microenvironment in the solid tumor. MSC secrete pleth-
ora of chemokines and growth factors which were already
linked to multiple regulatory functions in the tumor-
associated stroma [22]. MSC affect tumor cell morphology,
migratory potential and chemosensitivity [11].
In the present study we decided to examine in more de-
tail the secretome of the drug-exposed MSC and its po-
tential impact on the tumor cells based on the assumption
that the MSC become exposed to the drugs during antitu-
mor therapy in patients [12]. We propose that the
secretory stress response might be stimulated in the MSC,
as a part of tumor stroma, and thus should be considered
during therapy.
Results
Mesenchymal stromal cells (MSC) exposed to cisplatin did
not undergo apoptosis but underwent senescence
Based on the sensitivity of breast cancer cell lines (Fig. 1a)
we have chosen the concentration of 1 μg/ml cisplatin
(IC80 for almost all used cell lines) for pretreatment of
MSC. To examine the sensitivity of MSC to cisplatin, we
treated cells with 1 μg/ml cisplatin and 10-fold higher dose
(10 μg/ml). We have shown that MSC are resistant to 1 μg/
ml cisplatin by measuring Caspase-3/7 activity correspond-
ing to the induction of apoptosis in treated cells. Treatment
with 1 μg/ml cisplatin did not trigger apoptosis in MSC
within 48 h. MSC underwent apoptosis after more than
15 h exposure to 10 μg/ml cisplatin (Fig. 1b). The morph-
ology of cells treated with 1 μg/ml cisplatin remained un-
changed to control, in comparison to MSC treated with
10 μg/ml cisplatin (Fig. 1c).
We have observed that a part of MSC population under-
went senescence after 48 h treatment with 1 μg/ml cis-
platin (Fig. 2a). This phenomenon was described as the
senescence-associated phenotype in mesothelioma cells
describing a unique repertoire of molecules secreted by
senescent cells [23]. Senescence-associated phenotype has
not been described in mesenchymal stromal cells so far, as
well as complete response of MSC to chemotherapy pre-
treatment. In order to better characterize the molecular
response to cisplatin, we decided to analyse changes in
signaling and secretory profile in treated MSC.
Pre-exposed MSC activated several signaling cascades
and increased secretion of several cytokines
We have analyzed the phosphorylation of different kinases
and proteins in MSC and relative levels of 36 different cy-
tokines, chemokines, and acute phase proteins in condi-
tioned medium from the MSC pretreated with cisplatin
(pr.CM) in comparison to untreated MSC (CM). The MSC
were treated with 1 μg/ml cisplatin or kept in standard
medium overnight, and cell lysates were prepared subse-
quently. We observed significantly increased phosphoryl-
ation of PLC-y1, WNK1, RSK1/2/3, p53 and c-Jun in the
MSC treated with cisplatin overnight (Fig. 2b) indicating
that the drug exposure activated multiple pathways but did
not result in significant reduction of viability further
supporting the chemoresistant properties of MSC. This ob-
servation was supported by the analysis of the apoptosis-
related proteins in MSC. There were changes on both
levels of the pro- and anti-apoptotic proteins; however the
drug-pretreated MSC did not exhibit any indication of the
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pro-apoptotic signature (Fig. 2c). The analysis of condi-
tioned medium from pretreated MSC has shown elevated
levels of CXCL1, IL-6, IL-8, CCL2 and MIF cytokines in
comparison to control MSC (Fig. 2d). The level of other
cytokines remained unchanged or we were not able to de-
tect them in conditioned medium.
The effect of conditioned medium from pre-exposed MSC
on breast cancer cells
MSC express multiple genes responsible for invasive-
ness, survival, pluripotency, and mammosphere forma-
tion in breast cancer cells. Comparison of the growth
factor expression profile between the drug-exposed and
naïve MSC unraveled increased expression of the CCL5,
cMet, VEGFB and CXCL12 in MSC pretreated with cis-
platin (Fig. 3a).
Based on the substantial changes in gene expression of
drug-exposed MSC, we wanted to analyze the effect of
pr.CM on behavior of tumor cells in both indirect and dir-
ect co-culture. We started by the analysis of gene expres-
sion profile of tumor cells cultivated in the presence of
CM vs. pr.CM. We have observed increased expression of
CCL5 and cMet in tumor cells cultivated in the presence
of pr.CM compared to tumor cells cultivated in CM.
We examined whether upregulated cytokines had any
impact on the tumor cell sensitivity. Level of IL-6 and
IL-8 cytokines, increased in pr.CM, revealed the ability
to increase the resistance of MDA-MB-231 NucLight
Red™ cells to cisplatin (Fig. 4a). We have also shown
Fig. 1 a MDA-MB-231, Sk-Br-3, T47D and MCF-7 tumor cells were treated with cisplatin (0.1-50 μg/ml) diluted in standard culture medium. The
concentration of 1 μg/ml cisplatin (IC80 for almost all used cell lines) was set as a concentration used for pretreatment of MSC. b MSC were
pretreated with 1 μg/ml cisplatin or 10-fold higher dose (10 μg/ml). Measurement of Caspase-3/7 activity has shown that MSC are resistant to
1 μg/ml cisplatin by corresponding to the induction of apoptosis in evaluated cells. The treatment with 1 μg/ml cisplatin did not trigger apoptosis in
pretreated MSC within 48 h. MSC underwent apoptosis after more than 15 h exposure to 10 μg/ml cisplatin. c Using the IncuCyte Zoom™ Kinetic
Imaging System we have shown that the morphology of cells treated with 1 μg/ml cisplatin remained unchanged to control and the pretreatment
did not induce activation of fluorescence in cells because of missing caspase-3/7, in comparison to MSC treated with 10 μg/ml cisplatin
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changes in the stemness of tumor cells cultivated in
pr.CM. Conditioned medium from pre-exposed MSC in-
creased the number of ALDH positive MDA-MB-231
cells (10.8 % in pr.CM compared to 0.54 % in CM) and
MCF-7 cells (8.78 vs. 4.46 %) indicating increased popu-
lation of cancer stem-like cells (Fig. 4b). We have also
Fig. 2 a Untreated and 1 μg/ml cisplatin pretreated MSC were stained to detect β-Galactosidase activity at pH 6. We have shown that part of MSC
population underwent senescence after pretreatment. Cells were viewed by phase contrast in light microscope. Magnification 42x. b MSC were
overnight pretreated with 1 μg/ml cisplatin. Analysis of phosphorylation profiles of kinases and their protein substrates revealed their increased (RSK1/
2/3, WNK1, and other) or doubled (p53, c-Jun) concentration. c MSC overnight pretreated with 1 μg/ml cisplatin were analyzed for the relative level of
apoptosis-related proteins. The pretreatment with cisplatin caused small changes in expression of both pro-apoptotic and anti-apoptotic proteins.
d 48 h pretreatment of MSC with 1 μg/ml cisplatin increased the level of CXCL1, IL-6, IL-8, CCL2 and MIF cytokines released into MSC medium
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analyzed other stem cell-associated markers through im-
munostaining of CD24−/CD44+/EpCAM+ population in
Sk-Br-3 cell line cultivated in CM or pr.CM. Data re-
vealed increased median of fluorescence in CD24−/CD44
+/EpCAM+ population of Sk-Br-3 cells cultivated in con-
ditioned medium from pretreated MSC compared to
cells cultivated in conditioned medium from untreated
MSC (132.16 vs. 119.71) but no changes in a total num-
ber of CD24−/CD44+/EpCAM+ cells. It showed that cul-
tivation in pr.CM caused an increase in the number of
cell surface markers presented on the cells.
Direct co-culture of pre-exposed MSC and tumor cells
Following the analysis of indirect effect of MSC, we de-
cided to evaluate also the effect of direct co-culture of
tumor cells with untreated MSC or cisplatin pretreated
MSC. MSC were retrovirally transduced with RFP, and co-
cultured with tumor cells for 5 days. Subsequently, we
have sorted RFP-MSC and tumor cells based on the detec-
tion of RFP. The co-culture with the same batch of MSC,
which were only pretreated with cisplatin, caused signifi-
cant upregulation of expression of VEGFA, CDK2, GRB7
genes, and downregulation of NME1, MUC1, BRCA1,
CDKN2A, BIRC5, MYC, SERPINE1, NOTCH1 and XBP1
genes (at least 10-fold regulation) (Fig. 5a).
Pre-exposed MSC increased the resistance of breast
cancer cells in vivo
MSC alone were able to support the tumor growth of
breast cancer cells in vivo in comparison to control group.
The use of simultaneous treatment with cisplatin and
Fig. 3 a Pretreatment of the MSC increased the expression CCL5, cMet, VEGFB and CXCL12 genes compared to untreated MSC (set as a control).
b Cultivation of MCF-7 in pr.CM increased the expression of CCL5 and cMet compared to MCF-7 cultivated in CM. The expression of MCF-7
cultured under standard condition was set as a control. Gene expression was normalized to housekeeping genes β-actin and GAPDH
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Fig. 4 (See legend on next page.)
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injection of MSC led to increased resistance to cisplatin
and tumor volume of MDA-MB-231 cells (Fig. 5b).
Taken together our data suggest that MSC after treat-
ment with cisplatin are resistant to apoptosis, but activate
senescence-associated phenotype, concomitantly secreting
higher amounts of IL-6, IL-8, and other cytokines. This
contributed to increased tumor cell chemoresistance,
stemness and decreased response to chemotherapy in vivo.
Discussion
Tumors are considered as organ-like structures than just
a clonal expansion of mutant cells, and their microenvir-
onment represents an important issue for the develop-
ment of new therapeutic strategies [24, 25]. Tumor cells
and their stroma are exposed to the same physiological
or biological factors in the microenvironment and new
studies clearly demonstrate the impact of signals derived
from the cells of the tumor microenvironment on the
drug response of tumor cells [26, 27].
The chemoresistance of tumor cells leading to de-
creased therapeutic efficiency remains one of the major
obstacles in the treatment of cancer. The role of the
MSC as one of the cellular component in the tumor
stroma was described in both haemathological malignan-
cies and in solid tumors [28, 29]. The MSC within the
tumor microenvironment are exposed to the treatment
concomitantly with the tumor cells [10] and although
the chemoresistance of the MSC was described previ-
ously [15, 16], the stress response to the chemotherapy
was not characterized in detail. Although we have shown
that mesenchymal stromal cells are relatively resistant to
chemotherapy (Fig. 1b, c), they respond to the drug ex-
posure by several mechanisms. Our data showed that
pretreatment of MSC with cisplatin stimulated secretion
of different cytokines and changes in phosphorylation of
many kinases (Fig. 2b-d). It resulted in increased che-
moresistance and stemness of breast cancer cell lines in
vitro (Fig. 3a, b) and in vivo (Fig. 5b). We have shown,
that factors presented in pr.CM increase both the ALDH
positivity and expression of CD24−/CD44+/EpCAM+ cell
surface markers in tumor cells. It was demonstrated that
human breast cancers contain a cell population with
stem cells properties bearing the surface markers CD24
−/CD44+/lin− [30, 31]. Ginestier et al. [32] showed that
cells bearing the overlapping phenotype of ALDH-
positive and CD24−/CD44+/lin− had high tumorigenic
capacity and generated a tumor from as few as 20 cells.
We have characterized also the response of the MSC
on chemotherapeutics and especially the effect of the
soluble secreted factors released from the pretreated
MSC on the chemosensitivity of the breast cancer cells.
Roodhart et al. [10] showed that platinum-activated
MSC secrete unique fatty acids that confer the resist-
ance to multiple types of chemotherapy. Contrary to
our data, they did not observe any effect on the tumor
cells in in vitro model; and therefore suggested the re-
quirement of secondary secreted host factors.
Castells et al. [5] showed that MSC were able to protect
ovarian cells from apoptosis in response to carboplatin
after stabilization of the apoptosis-inhibitory proteins. We
have shown that MSC exposure to non-cytotoxic drug
concentrations activated several signaling cascades. MSC
pretreated with cisplatin showed increased phosphoryl-
ation of multiple tyrosine kinases such as PLC-y1, WNK1,
RSK1/2/3, c-Jun, STAT3 and p53 (Fig. 2b), which could
play a role in the MSC-mediated changes of tumor cells.
The active form of Y705F-STAT3 was shown to drive the
expression of many genes important in oncogenesis, cell
cycle control and the immune response. One of these
genes, CCL-5 (RANTES) was shown to be induced 42-
fold by Y705F-STAT3 [33]. We have shown increased
phosphorylation of Y705F-STAT3 in the MSC pretreated
with cisplatin, and also increased expression of CCL5 in
breast cancer cells cultivated in CM from pretreated MSC.
Increased expression of CCL5 by breast tumor cells is asso-
ciated with the disease progression, relapse, and metas-
tasis; and there was reported correlation between
STAT3-RANTES autocrine signaling and the acquisi-
tion of tamoxifen resistance through induction of anti-
apoptotic signal, which facilitated maintenance of drug
resistance [16, 34, 35]. Other influenced kinase, WNK1
was reported to be required for EGF-dependent stimula-
tion of ERK5 without affecting the activation of ERK1/2,
JNK or p38 MAP kinases [36]. Upregulated RSK family of
proteins also play an important role in many biological
functions, ranging from the regulation of transcription,
translation and protein stability to the control of cell sur-
vival, cell motility, cell growth and proliferation [37].
We suggest that MSC in the tumor microenvironment
respond to the stress mediated by chemotherapy by the
secretion of cytokines and chemokines reminiscent of a
senescence-associated secretory phenotype (SASP). SASP-
mediated chemoresistance was described in mesothelioma
cells [23] and we were able to detect β-Galactosidase ac-
tivity also in cisplatin pretreated MSC (Fig. 2a) in the
(See figure on previous page.)
Fig. 4 a MDA-MB-231 NucLight Red™ cells were treated with cisplatin (0.5 μg/ml) diluted in standard culture medium with/without 50 ng/ml IL-6, IL-8,
or both. The cytokines IL-6 and IL-8 were able to increase the resistance of MDA-MB-231 NucLight Red™ cells to cisplatin. b Flow cytometry
ALDEFLUOR® Assay has revealed increased ALDH activity in both MDA-MB-231 (10.8 % vs. 0.54 %) and MCF-7 cells (8.78 % vs. 4.46 %) cultivated in
conditioned medium from pre-exposed MSC in comparison to tumor cells cultivated in control CM
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Fig. 5 a MCF-7 cells and RFP-MSC (untreated or cisplatin pretretreated) were co-cultured for 5 days and subsequently sorted according to expression
of fluorescent marker. Gene expression array of 84 genes revealed statistically significant downregulation or upregulation of several genes (shown in
table). b We evaluated the effect of MSC-secreted factors also in vivo. Tumor bearing mice were treated with cisplatin (3 mg/kg) alone or in combination
with 250.000 of MSC. MSC were administered i.v. in the same day as chemotherapy. We found that administration of MSC reduced the therapeutic
effect of cisplatin
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absence of Caspase-3/7 activation. Laberge et al. [38]
showed that SASP-induced chemokines were able to influ-
ence neighboring cell population and tumor progression.
Even though the senescence was partial in the MSC popu-
lation, it was able to influence the level of important
chemokines and cytokines that triggered changes in the
exposed tumor cells. We have shown that exposure of
MSC to cisplatin increased the level of CXCL1, IL-6, IL-8,
CCL2 and MIF cytokines released into medium (Fig. 2d).
CCL2 together with CCL5 were shown to play an import-
ant role in breast malignancy and to mediate many types
of tumor-promoting cross-talks between the tumor cells
and cells of the tumor microenvironment [39]. Functional
analysis of tumor microenvironment revealed a correl-
ation between CCL5 levels and IL-6 levels [40]. We have
shown, that the increase of the resistance of tumor cells is
partially caused also with IL-6 and IL-8 (Fig. 3a). The im-
portance of the IL-6 and other cytokines as a prediction
factor of shorter progression-free survival was shown previ-
ously in patients with ovarian cancer [41] and breast cancer
(reviewed in [42]). The authors suggested the contribution
of IL-6 to ascites-mediated de novo drug resistance. Chen
et al. [43] demonstrated the role of IL-8 secreted in the
MSC conditioned medium in doxorubicin resistance in the
MDA-MB-231 cells. Thus the level of the IL-6 and IL-8
secretion may play an important role in the resistance me-
diated by the MSC exposed to chemotherapeutics.
These small changes in the level of important cyto-
kines may play a role in expression profile, stemness and
resistance of neighboring tumor cells to chemotherapy
and can help tumor cells to develop complex and per-
manent acquired resistance.
We have analyzed also the direct co-culture of tumor
cells with MSC, only pretreated with cisplatin, which chan-
ged the substantial expression of many genes compared to
tumor cells cultivated with untreated MSC (Fig. 5a). We
have shown increased expression of VEGFA, which play a
crucial role in the stimulation of angiogenesis via signaling
through VEGF receptor 2 [44], and GRB-7, which expres-
sion was shown to be strongly associated with decreased
survival of breast cancer patients [45]. The most downreg-
ulated gene NME1, a well-known metastasis suppressor
gene, was shown to regulate expression of genes important
for distant disease-free survival and overall survival in mel-
anoma and breast cancer [46].
We have shown that MSC alone were able to support
the tumor growth and resistance of breast cancer cells also
in vivo. But MSC are only one of the various cell types
that constitute the tumor microenvironment and through
cytokine production influence behavior of tumor cells. It
was shown that also macrophages are able to promote
metastatic seeding of breast cancer cells through CCL2-
triggered chemokine cascade [47] or endothelial cells,
which provide nutritional support to the growing tumor
[48]. Andre et al. [49] discussed the predictors of chemo-
sensitivity which could be derived from the microenvir-
onment, but none of these markers have shown a drug
specificity. They suggested a need to address the pre-
dictive value of these predictors in the context of bio-
marker studies.
Our experiments showed that cisplatin exposed MSC
were able to produce factors that turn on the changes in
stemness and resistance of tumor cells. We demon-
strated that this effect is not probably caused by single
specific molecule, but it is rather the result of the inter-
play among many cytokines concomitantly with small
changes in gene expression.
Conclusion
The tumor microenvironment is an extraordinarily het-
erogeneous and tumor cells are expected to experience
an array of microenvironmental cues, which will in turn
translate into several phenotypic manifestations. There is
a great deal of evidence that points to the stroma as a
major regulator of tumor progression and contributor to
the risk factors determining tumor formation. It is obvi-
ous that e.g., mesenchymal stromal cells, as a part of
tumor microenvironment, are exposed to therapy to-
gether with tumor cells and we can´t ignore the effects
of therapy on MSC. However, they pretend to be an in-
nocent bystanders, they smell what happens around, and
after activation via treatment they can influence the
tumor cells the way we haven´t expected. In conclusion,
MSC were relatively resistant to cisplatin and they did
not undergo apoptosis, but in contrast their secretion
profile have changed, what can be important to consider
when deciding the appropriate therapy for patients.
Methods
Cells
All chemicals were purchased from Sigma-Aldrich if not
stated otherwise. Human tumor cell lines MCF-7 (ATCC®
HTB-22™), Sk-Br-3 (ATCC® Number HTB-30™), T47D
(ATCC® HTB-133™), MDA-MB-231 (ATCC® HTB-26™)
and MDA-MB-231 NucLight Red™ (Essen BioScience,
Welwyn Garden City, UK) were used for the study. Mes-
enchymal stromal cells (MSC) were obtained from healthy
individuals undergoing elective lipoaspiration, who pro-
vided an informed consent. No humans were involved in
this research study, human material harvested from the
healthy individuals after elective surgery was used as
approved by the Ethics Committee of the University Hos-
pital (Ruzinov, Ruzinovska 6, 826 06 Bratislava, Slovakia).
MSC were isolated and characterized by the immuno-
phenotype and differentiation potential as previously
described in [22].
Stable transduction of MSC to express red fluorescent
protein (RFP) was done by retrovirus gene transfer.
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MSC culture was transduced three times in three con-
secutive days with virus containing media supplemented
with 1 μg/ml protamine sulphate. Cells were maintained
in selective media containing appropriate concentration
of G418 for 13 days, until the control (untransduced)
MSC were dead. Virus-containing medium was collected
from semi-confluent cultures of GP + env-AM-12/RFP
cells incubated in fresh culture medium for 24 h, filtered
through 0.45 μm filter and used either fresh or kept fro-
zen at −80 °C until use. RFP expression was confirmed
by flow cytometric analysis performed on BD Canto II
Cytometer (Becton Dicinson, USA).
Tumor cells were maintained in high-glucose (4.5 g/l)
DMEM (PAA Laboratories GmbH, Pasching, Austria)
containing 10 % FBS (GIBCO® Invitrogen, Carlsbad, CA),
10.000 IU/ml penicillin (Biotica, Part. Lupca, Slovakia),
5 μg/ml streptomycin, 2.5 μg/ml amphotericin and 2 mM
glutamine (PAA Laboratories GmbH). The MSC were
expanded in low glucose (1.0 g/l) DMEM supplemented
with 5 % HyClone® AdvanceSTEM™ supplement (Thermo
Scientific, Waltham, MA, USA) plus 5 % FBS and anti-
biotic/antimycotic mix (10,000 IU/ml penicillin, 5 μg/ml
streptomycin and 2.5 μg/ml amphotericin) and 2 mM
glutamine. Cells were maintained at 37 °C in humidified
atmosphere and 5 % CO2.
Cell-free MSC conditioned medium (CM) was col-
lected from 2 × 105 cells plated on a 35 mm culture dish
after 48 h of cultivation in high-glucose medium and
filtered through 0.45 μm filters. Fresh CM was always
used for the experiments.
Gene expression analysis
MSC were cultured with or without 1 μg/ml cisplatin
overnight. Total RNA was isolated from 4 × 106 cells. Cul-
tured cells were collected by trypsinization, RNA isolated
by NucleoSpin® RNA II kit (Macherey-Nagel, Germany)
and treated with RNase-free DNase (Qiagen, Hilden,
Germany). Total RNA was subjected to control PCR to
confirm the absence of genomic DNA contamination.
RNA was reverse transcribed with RevertAid™ H minus
First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot,
Germany). 200 ng of cDNA was amplified in standard
PCR performed in 8 μl 1x Dream Taq PCR Master Mix
(Thermo Scientific) with 0.3 μl respective specific primers
(20 pmol/μl) and DNase free water (Fermentas) in
BIORAD T100™ Thermal Cycler (MJ Research, UK) with
pre-set amplification profile, and horizontal electrophor-
esis was used for detection of amplicons.
For quantitative PCR we used following protocol: acti-
vation step at 95 °C for 3 min, 40 cycles of denaturation
at 95 °C for 5 s, 10 s annealing and polymerization at
58 °C and plate read for 5 s at 75 °C followed by final ex-
tension for 5 min at 72 °C and melt curve analysis. The
PCR reaction mixture (16 μl) contained 1,5 μl cDNA,
0,3 μl respective specific primers (10 pmol/μl), water
and Brilliant III QPCR SYBR® Green Mix (Agilent, Santa
Clara CA). qPCR reaction ran on CFX96™ Real-Time
PCR Detection System (BIO-RAD Laboratories, USA).
Drug resistance assay
For the evaluation of chemosensitivity of tumor cells, ei-
ther 5 × 103 Sk-Br-3, 1, 5 × 102 MDA-MB-231 (resp.
MDA-MB-231 NucLight Red™), 4 × 103 MCF-7 or 3 × 103
T47D cells were seeded in 96-well plates. On day 1, treat-
ments were started with cisplatin (0.1–50 μg/ml) diluted
in standard culture medium.
To test the effect of IL-6 and IL-8 on chemosensitivity,
1.5x102 MDA-MB-231 NucLight Red™ cells were seeded
in 96-well plates. On day 1, treatments were started with
cisplatin (0.5 μg/ml) diluted in standard culture medium
with/without 50 ng/ml IL-6, IL-8, or both.
IncuCyte Zoom™ Kinetic Imaging System and/or lumi-
nescence assay were used for analysis of treatment effects.
Kinetic measurement of Caspase-3/7 activity
To measure caspase-3/7 activity corresponding to the in-
duction of apoptosis in cells cultivated in the presence of
cisplatin, 7.5 × 103 MSC were seeded in 96-well plates and
treated with 1 and 10 μg/ml cisplatin. CellPlayer 96-Well
Kinetic Caspase-3/7 reagent (Essen BioScience) was used
at a final concentration of 5 μM in growth medium and
added directly to cells in 96-well plates. Caspase-3/7
reagent is non- fluorescent substrate which crosses the
cell membrane where it is cleaved by activated caspase-3/
7 resulting in the release of the DNA dye and green fluor-
escent staining of nuclear DNA. Kinetic activation of
caspase-3/7 was monitored using IncuCyte Zoom™ Kinetic
Imaging System and quantified using the IncuCyte™ FLR
object counting algorithm.
Senescence β-Galactosidase Staining
MSC were examined also for the presence of senescent
cells with the Senescence β-Galactosidase Staining Kit (Cell
Signaling Technology). Three × 105 MSC were seeded per
well in low glucose DMEM in 6-well plate, and the next
day treated with/without 1 μg/ml cisplatin in standard cul-
ture medium for 48 h. The β-Galactosidase activity was de-
tected at pH 6 by light microscopy; the blue color
development indicated β-Gal-positive senescent cells.
Flow cytometry
ALDH activity
ALDH activity was measured in MDA-MB-231 and MCF-
7 cells cultivated in standard medium, CM or pretreated
CM (pr.CM) after reaching confluence (after 4–5 days).
Four hundred thousand cells were seeded on a 35 mm
culture dish in standard medium, which was replaced by
fresh 5 ml of standard medium, CM or pr.CM the next
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day. Flow cytometry ALDEFLUOR® Assay (StemCell
Technologies, Vancouver, BC) was used to assess ALDH
activity. Control cells were exposed to diethylaminoben-
zaldehyde (DEAB) prior measurement. Two hundred fifty
thousand cells were centrifuged for 5 min at 250 x g, the
supernatant was removed and the cells were suspended in
500 μl of ALDEFLUOR Assay buffer.
Measurement was performed using BD FACSCanto™
II Flow cytometer (Becton Dickinson, USA) equipped
with FacsDiva program. Data were analysed with FCS
Express program.
CD24−/CD44+/EpCAM+ activity
Sk-Br-3 cells were cultivated in standard CM or pr.CM for
5 days. CD24-PE, CD44-APC and EpCAM-FITC antibody
(Miltenyi Biotec GmbH, Germany) were used at a 1:50 di-
lution and incubated for 15 min with 250.000 tumor cells
per sample. Triple staining was used for analysis of CD24
−/CD44+/EpCAM+ population on BD FACSCanto™ II
Flow cytometer (Becton Dickinson, USA).
Proteomic arrays
Analysis of phosphorylation profiles of kinases and their
protein substrates, as well as analysis of expression of
apoptosis-related proteins was done by the Human
Phospho-Kinase Array (R&D Systems, Minneapolis, MN)
and Human Apoptosis Array Kit (R&D Systems). For
both, untreated and overnight 1 μg/ml cisplatin pretreated
MSC were solubilized at 1 × 107 cells/ml in lysis buffer at
2–8 °C for 30 min and proceeded according to manufac-
turer’s protocol. ImageJ software (NIH, Bethesda, MD)
was used for the quantitative evaluation; pixel density was
determined and calculated.
Cell supernatant of untreated MSC and pretreated
MSC as above was analyzed by Human Cytokine Array
Kit (R&D Systems) used to simultaneously detect the
relative levels of 36 different cytokines, chemokines, and
acute phase proteins according manufacturers protocol.
Gene expression array
For evaluation of the effect of direct co-culture of tumor
cells with MSC (untreated or pretreated with 1 μg/ml cis-
platin), 200.000 of MCF-7 were cultivated with 200.000 of
RFP-MSC for 5 days and then sorted on BD Influx (BD
Biosciences, USA) based on RFP positivity. Excitation
laser was 561 nm and emission filter 585/29. RNA from
MCF-7 cells were then isolated by Agilent Total RNA
Isolation Mini Kit (Agilent Technologies, USA). RNA
was reverse transcribed with RT2 Profiler PCR Array
and expression of 84 human breast cancer related genes
was analyzed.
In vivo experiments
Six week old athymic nude mice (Balb/c-nu/nu) were used
in accordance with the institutional guidelines under the
approved protocols. Five x106 MDA-MB-231 cells were
injected subcutaneously in 100 μl serum free DMEM
(PAA Laboratories GmbH). Animals were subsequently
divided into following groups: control group (n = 4), cis-
platin i.p. alone (n = 5), i.v. 2.5 × 105 MSC with i.p. cis-
platin (n = 6), i.v. 2.5 x105 MSC alone (n = 4). Animals
were treated with 3 mg/kg cisplatin with/without MSC
every 12, 19 and 26 day.
Animals were regularly inspected for the tumor growth
and the tumor volume was calculated according to the
formula volume = length x width2/2. Animals were sacri-
ficed, when the tumors exceeded 1 cm3 in accordance
with the ethical guidelines.
Project was performed in the approved animal fa-
cility (licence number SK PC 14011) as approved by
the institutional ethic committee and by the national
competence authority (State Veterinary and Food
Administration of the Slovak Republic, registration
number Ro 3108/14-221) in compliance with the
Directive 2010/63/EU of the European Parliament
and the European Council and the Regulation 377/
2012 on the protection of animals used for scientific
purposes.
Statistical analysis
Studies involving comparison between the two groups
were analyzed by an unpaired Student's t-test in GraphPad
Prism® software (LA Jolla, CA). The value of p < 0.05 was
considered statistically significant.
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